Program
dexamethasone phosphate
Also written as “Moxidex otic solution”, “Dexamethasone sodium phosphate” and “Dexamethasone Phosphate Ophthalmic Solution”.
Its studies are mostly in Otitis Media · Ataxia Telangiectasia · Peripheral Arterial Disease · Uveitis, Anterior · Cataract, led by 5 companies.
Drug pageDexamethasone phosphate: every studyMany companies study it; this page follows only the 20 they lead. All 66 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eyegate Pharmaceuticalsits history only | 70 open or running | phase 3since May 20, 2010 | Jun 5, 2008 | none ahead |
| Alconits history only | 60 open or running | phase 3since Dec 19, 2007 | Dec 19, 2007 | none ahead |
| Quince Therapeuticsits history only | 30 open or running | phase 3since Dec 11, 2023 | Jul 28, 2010 | none ahead |
| Mercator MedSystems | 20 open or running | phase 4since Nov 4, 2013 | Nov 4, 2013 | none ahead |
| Taiwan Liposomeits history only | 20 open or running | phase 2since Nov 13, 2013 | Nov 13, 2013 | none ahead |
Also a collaborator on its studies: Biotrial.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Mercator MedSystems only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 4, 2013First study: phase 4 study in Peripheral Arterial DiseaseFirst studyNCT01983449 · 285 enrolled · United States
- May 6, 2019Phase 2 study in Peripheral Arterial DiseaseNCT03942601 · 10 enrolled · United States
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
All 2 Mercator MedSystems leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03942601Peripheral Arterial Disease · United States | 2 | Terminated | Apr 30, 2021 | 10 |
| NCT01983449Peripheral Arterial Disease · United States | 4 | Completed | Dec 2016 | 285 |
How it is read
Names in the registry
- “Moxidex otic solution”, 5 entries
- “Dexamethasone sodium phosphate”, 2 entries
- “Dexamethasone Phosphate Ophthalmic Solution”, 2 entries
- “Low-dose TGF-B3 and Dexamethasone Sodium Phosphate”, 1 entry
- “High-dose TGF-B3 and Dexamethasone Sodium Phosphate”, 1 entry
Conditions, from the studies’ own filings
- Otitis Media, 4 studies
- Ataxia Telangiectasia, 2 studies
- Peripheral Arterial Disease, 2 studies
- Uveitis, Anterior, 2 studies
- Cataract, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.